• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
HIV-1 Infection - Pipeline Review, H2 2012 Product Image

HIV-1 Infection - Pipeline Review, H2 2012

  • Published: August 2012
  • 287 pages
  • Global Markets Direct

HIV-1 Infection – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'HIV-1 Infection - Pipeline Review, H2 2012', provides an overview of the HIV-1 Infection therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. 'HIV-1 Infection - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV-1 Infection.
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
HIV-1 Infection Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for HIV-1 Infection 11
HIV-1 Infection Therapeutics under Development by Companies 13
HIV-1 Infection Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
HIV-1 Infection Therapeutics – Products under Development by Companies 24
HIV-1 Infection Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in HIV-1 Infection Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Abbott Laboratories 34
GlaxoSmithKline plc 35
Inovio Biomedical Corporation 36
Gilead Sciences, Inc. 37
Merck & Co., Inc. 38
United Biomedical, Inc. 39
Aphios Corporation 40
Pfizer Inc. 41
Avexa Limited 42
Koronis Pharmaceuticals, Inc. 43
Alfacell Corporation 44
Geron Corporation 45
GeoVax Labs, Inc. 46
ConjuChem Biotechnologies Inc. 47
Critical Outcome Technologies Inc. 48
Takara Bio Inc. 49
Functional Genetics, Inc. 50
BioClonetics Incorporated 51
Nutri Pharma ASA 52
Vironova AB 53
Argos Therapeutics, Inc. 54
Myriad Pharmaceuticals, Inc. 55
GeneCure LLC 56
Tobira Therapeutics, Inc. 57
ViiV Healthcare 58
RFS Pharma, LLC 59
Vichem Chemie Research Ltd. 60
HIV-1 Infection – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
1265744 - Drug Profile 68
MPI-461359 - Drug Profile 69
pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine - Drug Profile 70
Amdoxovir - Drug Profile 72
TBR-652 - Drug Profile 73
AGS-004 - Drug Profile 75
Apricitabine - Drug Profile 77
Raltegravir + Tenofovir + Lamivudine - Drug Profile 78
Tenofovir + Emtricitabine + Efavirenz - Drug Profile 80
Autologous HIV-1 ApB DC Vaccine - Drug Profile 82
Lopinavir + Ritonavir - Drug Profile 83
Dapivirine Ring - Drug Profile 84
Zidovudine + Lamivudine + Nevirapine - Drug Profile 86
Truvada + Darunavir + Ritonavir + Maraviroc + Raltegravir - Drug Profile 87
Gardasil - Drug Profile 89
Dendritic Cell Vaccine + GM-CSF + Interferon Alpha - Drug Profile 90
mRNA-Transfected Autologous Dendritic Cells - Drug Profile 91
MVA.HIVA Vaccine - Drug Profile 92
Etravirine + Nucleoside + Nucleotide Reverse Transcriptase Inhibitors - Drug Profile 93
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile 95
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile 96
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile 97
VRC-HIVADV014-00-VP - Drug Profile 99
Stavudine + Lamivudine + Abacavir - Drug Profile 100
Emtricitabine + Tenofovir - Drug Profile 101
Tenofovir - Drug Profile 102
Stavudine + Lamivudine + Nevirapine - Drug Profile 103
Abacavir + Lamivudine + Nevirapine - Drug Profile 104
Zidovudine + Lamivudine + Abacavir - Drug Profile 106
Emend - Drug Profile 107
Didanosine + Abacavir + Kaletra - Drug Profile 109
Zidovudine + Lamivudine + Kaletra - Drug Profile 111
Lamivudine + Didanosine + Efavirenz - Drug Profile 113
Lamivudine + Recombinant Hepatitis B Surface Antigen - Drug Profile 114
Raltegravir + Lopinavir + Ritonavir - Drug Profile 115
Isentress + Kaletra - Drug Profile 116
Vacc-4x - Drug Profile 117
Ad35-GRIN/ENV HIV Vaccine - Drug Profile 119
VRC-HIVDNA-016-00-VP + VRCHIVADV014-00-VP - Drug Profile 120
Atazanavir + Raltegravir + Lamivudine - Drug Profile 121
Atazanavir + Raltegravir + Emtricitabine - Drug Profile 122
Lopinavir + Ritonavir + Zidovudine - Drug Profile 124
Abacavir + Zidovudine - Drug Profile 125
BMS-663068 - Drug Profile 127
BMS-663068 + Ritonavir - Drug Profile 129
Darunavir + Ritonavir - Drug Profile 130
Raltegravir + Darunavir + Etravirine + NRTIs + Enfuvirtide - Drug Profile 131
TUTI-16 - Drug Profile 132
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile 133
TMC310911 + Ritonavir - Drug Profile 134
KP-1461 - Drug Profile 135
Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile 137
PENNVAX-B DNA Vaccine - Drug Profile 139
EP HIV-1043 - Drug Profile 140
EP HIV-1043 + EP HIV-1090 - Drug Profile 141
EP HIV-1090 - Drug Profile 142
rAd5 env A + rAd5 env B - Drug Profile 143
GTU-MultiHIV B Clade Vaccine + Interleukin-2 + GM-CSF + Growth Hormone - Drug Profile 145
PENNVAX-B + GENEVAX IL-12-4532 - Drug Profile 147
PENNVAX-B + GENEVAX IL-12-4532 - Drug Profile 148
SAAVI DNA-C2 Vaccine + SAAVI MVA-C Vaccine - Drug Profile 149
Kaletra - Drug Profile 150
Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile 152
Viread + Aluvia - Drug Profile 154
Truvada + Nevirapine - Drug Profile 156
Truvada + Zidovudine - Drug Profile 158
ALVAC-HIV vCP1521 - Drug Profile 160
MVA.HIVconsv - Drug Profile 161
TBC-M4 - Drug Profile 162
AD100-GP96IG-HLA A1 Vaccine - Drug Profile 163
ChAdV63.HIVconsv + pSG2.HIVconsv + MVA.HIVconsv - Drug Profile 164
Fuzeon + Truvada + Kaletra - Drug Profile 165
rAd35 Env A - Drug Profile 167
rAd35 Env A + rAd5 Env A - Drug Profile 169
rAd5 Env A - Drug Profile 171
Tenofovir + Emtricitabine - Drug Profile 172
GS-7340 - Drug Profile 173
Isentress + Tenofovir + Lamivudine - Drug Profile 174
HIV gp120/NefTat/AS02A Vaccine - Drug Profile 176
ART Regimen + Raltegravir + Maraviroc - Drug Profile 178
KD-247 - Drug Profile 180
HIV-1 Integrase Inhibitor Program - Drug Profile 181
ART Regimen + Raltegravir + Maraviroc + Interleukin-7 - Drug Profile 183
Zinc Supplementation - Drug Profile 185
Intelence + Truvada - Drug Profile 186
Autologous CD4-ZETA Gene Modified T Cells + Interleukin-2 - Drug Profile 188
Intelence + Ritonavir + Atazanavir + NRTI - Drug Profile 190
UB-421 - Drug Profile 191
HIV-1 Drug Development Programme - Drug Profile 192
TAT0002 - Drug Profile 193
Celsentri + Antiretroviral Therapy - Drug Profile 195
UK-453061 + Tenofovir DF + Emtricitabine - Drug Profile 197
DACHIV - Drug Profile 199
Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile 200
GSK732462 - Drug Profile 202
572-Trii - Drug Profile 203
Antiretroviral Therapy + Pegintron - Drug Profile 205
TBR 652 + Truvada - Drug Profile 206
APH-0812 - Drug Profile 208
Reyataz + Cobicistat - Drug Profile 209
Cobicistat + Prezista - Drug Profile 211
Vorinostat - Drug Profile 212
HIV-1 Therapeutic Vaccine - Drug Profile 213
Leukothera - Drug Profile 214
BMS-663068 + Raltegravir + Tenofovir - Drug Profile 215
KP-1212 - Drug Profile 217
Recombinant Amphinase 2 - Drug Profile 218
HIVAX - Drug Profile 220
Lersivirine + Darunavir + Ritonavir + NRTI - Drug Profile 222
MK-1439 - Drug Profile 224
CDK9 Inhibitors - Drug Profile 225
BMS-986001 + Sustiva + Lamivudine - Drug Profile 227
Etravirine - Drug Profile 229
VAC-3S - Drug Profile 230
MazF-Based HIV-1 Gene Therapy - Drug Profile 231
AFO18–CAF01 Vaccine - Drug Profile 233
GTU-MultiHIV B + LIPO-5 - Drug Profile 235
Rifaximin - Drug Profile 236
FGI-111 Program - Drug Profile 237
CLONE 3 - Drug Profile 238
Atazanavir + Lamivudine + Ritonavir - Drug Profile 240
HIV-1 Infection Therapeutics – Drug Profile Updates 241
HIV-1 Infection Therapeutics – Discontinued Products 253
HIV-1 Infection Therapeutics - Dormant Products 255
HIV-1 Infection – Product Development Milestones 266
Featured News & Press Releases 266
Appendix 278
Methodology 278
Coverage 278
Secondary Research 278
Primary Research 278
Expert Panel Validation 278
Contact Us 279
Disclaimer 279

List of Tables
Number of Products Under Development for HIV-1 Infection, H2 2012 19
Products under Development for HIV-1 Infection – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 27
Comparative Analysis by Late Stage Development, H2 2012 28
Comparative Analysis by Mid Clinical Stage Development, H2 2012 29
Comparative Analysis by Early Clinical Stage Development, H2 2012 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Development by Companies, H2 2012 (Contd..1) 33
Products under Development by Companies, H2 2012 (Contd..2) 34
Products under Investigation by Universities/Institutes, H2 2012 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 39
Bristol-Myers Squibb Company, H2 2012 40
Johnson & Johnson, H2 2012 41
Abbott Laboratories, H2 2012 42
GlaxoSmithKline plc, H2 2012 43
Inovio Biomedical Corporation, H2 2012 44
Gilead Sciences, Inc., H2 2012 45
Merck & Co., Inc., H2 2012 46
United Biomedical, Inc., H2 2012 47
Aphios Corporation, H2 2012 48
Pfizer Inc., H2 2012 49
Avexa Limited, H2 2012 50
Koronis Pharmaceuticals, Inc., H2 2012 51
Alfacell Corporation, H2 2012 52
Geron Corporation, H2 2012 53
GeoVax Labs, Inc., H2 2012 54
ConjuChem Biotechnologies Inc., H2 2012 55
Critical Outcome Technologies Inc., H2 2012 56
Takara Bio Inc., H2 2012 57
Functional Genetics, Inc., H2 2012 58
BioClonetics Incorporated, H2 2012 59
Nutri Pharma ASA, H2 2012 60
Vironova AB, H2 2012 61
Argos Therapeutics, Inc., H2 2012 62
Myriad Pharmaceuticals, Inc., H2 2012 63
GeneCure LLC, H2 2012 64
Tobira Therapeutics, Inc., H2 2012 65
ViiV Healthcare, H2 2012 66
RFS Pharma, LLC, H2 2012 67
Vichem Chemie Research Ltd., H2 2012 68
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Stage and Route of Administration, H2 2012 72
Assessment by Stage and Molecule Type, H2 2012 75
HIV-1 Infection Therapeutics – Drug Profile Updates 249
HIV-1 Infection Therapeutics – Discontinued Products 261
HIV-1 Infection Therapeutics – Discontinued Products (Contd..1) 262
HIV-1 Infection Therapeutics – Dormant Products 263
HIV-1 Infection Therapeutics – Dormant Products (Contd..1) 264
HIV-1 Infection Therapeutics – Dormant Products (Contd..2) 265
HIV-1 Infection Therapeutics – Dormant Products (Contd..3) 266
HIV-1 Infection Therapeutics – Dormant Products (Contd..4) 267
HIV-1 Infection Therapeutics – Dormant Products (Contd..5) 268
HIV-1 Infection Therapeutics – Dormant Products (Contd..6) 269
HIV-1 Infection Therapeutics – Dormant Products (Contd..7) 270
HIV-1 Infection Therapeutics – Dormant Products (Contd..8) 271
HIV-1 Infection Therapeutics – Dormant Products (Contd..9) 272
HIV-1 Infection Therapeutics – Dormant Products (Contd..10) 273

List of Figures
Number of Products under Development for HIV-1 Infection, H2 2012 19
Products under Development for HIV-1 Infection – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 25
Late Stage Products, H2 2012 28
Mid Clinical Stage Products, H2 2012 29
Early Clinical Stage Products, H2 2012 30
Discovery and Pre-Clinical Stage Products, H2 2012 31
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Route of Administration, H2 2012 71
Assessment by Stage and Route of Administration, H2 2012 72
Assessment by Molecule Type, H2 2012 73
Assessment by Stage and Molecule Type, H2 2012 74

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos